Clinical trial · Observational
Precision Medicine for L/GCMN and Melanoma 2
Precision Medicine for L/GCMN and Melanoma 1 (Precis-mel 2)
NCT06605443CI-TRIAL-00086546Precis-mel 2recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Congenital Melanocytic Nevus | Congenital Cutaneous Nevus | ALIAS | 0.90 |
| Melanoma (Skin Cancer) | Melanoma | ONTOLOGY_EXACT | 0.85 |
| Nevi and Melanomas | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breath analyzer | Device | — | UNRESOLVED |
| Liquid biopsy | Genetic | — | UNRESOLVED |
| Skin patch | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Melanoma (non-metastatic)
- description
- Patients of either sex over 18 years old with histopathological confirmed melanoma in a non metastatic stage (I to IIb stages according to AJCC classification)
- interventionNames
- Device: Breath analyzer
- Device: Skin patch
- Genetic: Liquid biopsy
- label
- Melanoma (metastatic)
- description
- Patients of either sex over 18 years old with histopathological confirmed melanoma in a metastatic stage (IIIa to IV stages according to AJCC classification)
Primary outcomes (1)
- measure
- Early identification of metastases
- timeFrame
- 24 months
- description
- The primary objective of the study is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Be over 18 years old * Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC) Exclusion Criteria: * Not signing the informed consent form * Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles
References
Publications (0)
Data not yet available
No reference posted for this study.